Guggenheim Reiterates Buy Rating on Bristol-Myers Squibb Company (BMY)

Market Context

Bristol-Myers Squibb Company operates in the Healthcare sector. The stock currently trades at $64.74 with a market capitalization of $104.2B. The stock has gained 34.8% over the past 52 weeks.

Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Bristol-Myers Squibb Company.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Bristol-Myers Squibb Company

Among the 10 most recent ratings: 5 Buy, 5 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 31, 2026	Wells Fargo	Equal-Weight	N/A
Jul 31, 2026	Truist Securities	Buy	N/A
Jul 31, 2026	Guggenheim	Buy	N/A
Jul 10, 2026	B of A Securities	Buy	N/A
Jul 06, 2026	Cantor Fitzgerald	Neutral	N/A

Related Tools: Analyst Ratings Dashboard | View BMY Stock Page